Category: <span>malignant pleural mesothelioma treatment</span>

Category: malignant pleural mesothelioma treatment

chemotherapy for mesothelioma, immunotherapy for mesothelioma, malignant pleural mesothelioma treatment, Mesothelioma News, second line mesothelioma treatment, sellas life sciences group, wt1 vaccine

FDA Speeds Possible Second-Line Treatment for Mesothelioma

 

The U.S. Food and Drug Administration awarded Fast Track designation recently to the WT1 cancer vaccine, moving it closer to becoming the first approved second-line treatment for malignant pleural mesothelioma. The vaccine, also known as galinpepimut-S, is an immunotherapy agent that targets the WT1 protein, which is expressed in high levels in various cancers, such…

The post FDA Speeds Possible Second-Line Treatment for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

malignant pleural mesothelioma treatment, mesothelioma cancer, mesothelioma chemotherapy, mesothelioma clinical trial, Mesothelioma News, Mesothelioma treatment, nintedanib, Ofev, rama balaraman

Researchers Test Nintedanib in Mesothelioma Clinical Trial

 

Medical oncologist Dr. Rama Balaraman isn’t expecting any miracles from the pleural mesothelioma clinical trial involving nintedanib, the small-molecule enzyme inhibitor. She is expecting progress. Balaraman, at Florida Cancer Affiliates in Ocala, is participating in an international, multicenter trial that will expand the use of nintedanib within the U.S., giving patients another weapon in this…

The post Researchers Test Nintedanib in Mesothelioma Clinical Trial appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

cancer treatment, city of hope cancer center, clinical trials at memorial sloan kettering, clinical trials in california, malignant pleural mesothelioma treatment, marianna koczywas, mesothelioma clinical trial, Mesothelioma News, Tazemetostat

Mesothelioma Clinical Trial for Tazemetostat Launches in US

 

City of Hope cancer center thoracic oncologist Dr. Marianna Koczywas explains the workings of tazemetostat — the latest drug tested in a mesothelioma clinical trial — with the lock and key metaphor. “You have a specific [cancer] key, and a specific keyhole it goes through. If you can lock that keyhole, you can lock it…

The post Mesothelioma Clinical Trial for Tazemetostat Launches in US appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.